Compare Liberty Media Corporation Series C Liberty Formula One Common Stock (FWONK) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liberty Media Corporation Series C Liberty Formula One Common Stock vs Vertex Pharmaceuticals Incorporated — how do they compare? Liberty Media Corporation Series C Liberty Formula One Common Stock trades at $90.85 (market cap $22.59B), while Vertex Pharmaceuticals Incorporated trades at $505.49 (market cap $126.35B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 5.6× Liberty Media Corporation Series C Liberty Formula One Common Stock's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Liberty Media Corporation Series C Liberty Formula One Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Media Corporation Series C Liberty Formula One Common Stock for 0 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| FWONK | VRTX | |
|---|---|---|
Market Cap | $22.59B | $126.35B |
Volume | 2,257,903 | 2,089,984 |
Sector | Media | Health |
52-Week High | $106.66 | $557.96 |
52-Week Low | $81.42 | $407.90 |
Typical Hold Time | 0 Days | 120 Days |
Enterprise Value | $26.05B | $120.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Vertex Pharmaceuticals (VRTX) trades at $485.22, down 4.3% amid a bearish technical signal, though fundamentals remain strong with 2025 revenue of $12.0B and net income of $3.95B. The company maintains dominant cystic fibrosis market position and shows positive Phase II data for kidney disease drug inaxaplin. Analyst consensus is strongly bullish with 85.7% buy ratings and $573.50 price target, representing 18% upside potential from current levels.
Vertex presents a compelling growth story with robust profitability (35% net margin) and expanding pipeline, though recent earnings misses and competitive pressures warrant caution. The stock's current dip may offer entry opportunity for long-term investors, with key catalysts including regulatory decisions and pipeline advancements expected in early 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Liberty Media Corporation Series C Liberty Formula One Common Stock
Liberty Media Corporation's Series C Liberty Formula One common stock is a tracking stock reflecting the economic performance of the Formula One Group, which holds Liberty Media's interests in Formula 1 racing, MotoGP, and related minority investments.
Read more on FWONK →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
